Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
Michael Timaner(Technion – Israel Institute of Technology), Yuval Shaked(Technion – Israel Institute of Technology), Ofrat Beyar‐Katz(Rambam Health Care Campus), Nitzan Letko-Khait(Technion – Israel Institute of Technology), Ziv Raviv(Tel Aviv University), Madeleine Benguigui(Technion – Israel Institute of Technology), Marcelle Machluf(Technion – Israel Institute of Technology), Chen Rachman-Tzemah(Technion – Israel Institute of Technology), Tomer Bronshtein(Technion – Israel Institute of Technology), Ruslana Kotsofruk(Technion – Israel Institute of Technology)
Cited by 103
Related Papers
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
|Blood Advances|2021|170
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
|Transplantation and Cellular Therapy|2021|164
Cultured meat platform developed through the structuring of edible microcarrier-derived microtissues with oleogel-based fat substitute
|Nature Communications|2023|110
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
|Leukemia|2019|69
Novel Approaches to Acute Myeloid Leukemia Immunotherapy
|Clinical Cancer Research|2018|63